Adenoviral vectors deleted of all their viral genes (helper-dependent [HD]) are efficient gene-transfer vehicles. Because transgene expression is rapidly lost in actively dividing cells, we investigated the feasibility of using phage φC31 integrase (φC31-Int) to integrate an HD carrying an attB site and the puromycin resistance gene into human cells (HeLa) and murine myoblasts (C2C12) by co-infection with a second HD-expressing φC31-Int. Because the HD genome is linear, we also investigated whether its circularization, through expression of Cre using a third HD, affects integration. Efficacy and specificity were determined by scoring the number of puromycin-resistant colonies and by sequencing integration sites. Unexpectedly, circularization of HD was unnecessary and it even reduced the integration efficacy. The maximum integration efficacy achieved was 0.5% in HeLa cells and 0.1% in C2C12 myoblasts. Up to 76% of the integration events occurred at pseudo attP sites and previously characterized hotspots were found. A small (two- to three-fold) increase in the number of γ-H2AX positive foci, accompanied by no noticeable change in γ-H2AX expression, indicated the low genotoxicity of φC31-Int. In conclusion, integration of HD mediated by φC31-Int is an attractive alternative to engineer cells, because it permits site-specific integration of large DNA fragments with low genotoxicity.
Robert and colleagues investigate the feasibility of using phage φC31 integrase to integrate a helper-dependent (HD) adenoviral vector into mammalian cells. Using this approach, the authors are able to achieve an integration efficacy of 0.5% and 0.12% in HeLa cells and C2C12 myoblasts, respectively. Moreover, they report that up to 76% of the integration events occur at pseudo attP sites and previously characterized hot spots.
Get full access to this article
View all access options for this article.
References
1.
Al YacoubN., RomanowskaM., HaritonovaN.et al.2007. Optimized production and concentration of lentiviral vectors containing large inserts. J Gene Med, 9:579–584.
2.
AndreasS., SchwenkF., Kuter-LuksB.et al.2002. Enhanced efficiency through nuclear localization signal fusion on phage PhiC31-integrase: activity comparison with Cre and FLPe recombinase in mammalian cells. Nucleic Acids Res, 30:2299–2306.
3.
AnejaM.K., ImkerR., RudolphC.2007. Phage phiC31 integrase-mediated genomic integration and long-term gene expression in the lung after nonviral gene delivery. J Gene Med, 9:967–975.
4.
BertoniC., JarrahianS., WheelerT.M.et al.2006. Enhancement of plasmid-mediated gene therapy for muscular dystrophy by directed plasmid integration. Proc Natl Acad Sci U S A, 103:419–424.
5.
CalosM.P.2006. The phiC31 integrase system for gene therapy. Curr Gene Ther, 6:633–645.
6.
ChalbergT.W., PortlockJ.L., OlivaresE.C.et al.2006. Integration specificity of phage phiC31 integrase in the human genome. J Mol Biol, 357:28–48.
7.
ChenJ.Z., JiC.N., XuG.L.et al.2006. DAXX interacts with phage PhiC31 integrase and inhibits recombination. Nucleic Acids Res, 34:6298–6304.
8.
DeolJ.R., DanialouG., LarochelleN.et al.2007. Successful compensation for dystrophin deficiency by a helper-dependent adenovirus expressing full-length utrophin. Mol Ther, 15:1767–1774.
9.
DropulicB.2011. Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research. Hum Gene Ther, 22:649–657.
10.
EhrhardtA., XuH., HuangZ.et al.2005. A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase phiC31 and the Sleeping Beauty transposase. Mol Ther, 11:695–706.
11.
EhrhardtA., EnglerJ.A., XuH.et al.2006. Molecular analysis of chromosomal rearrangements in mammalian cells after phiC31-mediated integration. Hum Gene Ther, 17:1077–1094.
12.
EhrhardtA., YantS.R., GieringJ.C.et al.2007. Somatic integration from an adenoviral hybrid vector into a hot spot in mouse liver results in persistent transgene expression levels in vivo. Mol Ther, 15:146–156.
13.
FredmanJ.N., EnglerJ.A.1993. Adenovirus precursor to terminal protein interacts with the nuclear matrix in vivo and in vitro. J Virol, 67:3384–3395.
14.
GilbertR., NalbantogluJ., HowellJ.M.et al.2001. Dystrophin expression in muscle following gene transfer with a fully deleted (“gutted”) adenovirus is markedly improved by trans-acting adenoviral gene products. Hum Gene Ther, 12:1741–1755.
15.
GilbertR., LiuA., PetrofB.et al.2002. Improved performance of a fully gutted adenovirus vector containing two full-length dystrophin cDNAs regulated by a strong promoter. Mol Ther, 6:501–509.
16.
GilbertR., DudleyR.W., LiuA.B.et al.2003. Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin. Hum Mol Genet, 12:1287–1299.
17.
GoncalvesM.A., HolkersM., Van NieropG.P.et al.2008. Targeted chromosomal insertion of large DNA into the human genome by a fiber-modified high-capacity adenovirus-based vector system. PLoS One, 3:e3084.
18.
GrothA.C., OlivaresE.C., ThyagarajanB.et al.2000. A phage integrase directs efficient site-specific integration in human cells. Proc Natl Acad Sci U S A, 97:5995–6000.
19.
HaruiA., SuzukiS., KochanekS.et al.1999. Frequency and stability of chromosomal integration of adenovirus vectors. J Virol, 73:6141–6146.
20.
HeldP.K., OlivaresE.C., AguilarC.P.et al.2005. In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery. Mol Ther, 11:399–408.
21.
HillgenbergM., TonniesH., StraussM.2001. Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer. J Virol, 75:9896–9908.
22.
IshikawaY., TanakaN., MurakamiK.et al.2006. Phage phiC31 integrase-mediated genomic integration of the common cytokine receptor gamma chain in human T-cell lines. J Gene Med, 8:646–653.
23.
KeravalaA., ChavezC.L., HuG.et al.2011. Long-term phenotypic correction in factor IX knockout mice by using phiC31 integrase-mediated gene therapy. Gene Ther, 18:842–848.
24.
KreissP., CameronB., RangaraR.et al.1999. Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic Acids Res, 27:3792–3798.
25.
KreppelF., KochanekS.2004. Long-term transgene expression in proliferating cells mediated by episomally maintained high-capacity adenovirus vectors. J Virol, 78:9–22.
26.
LiuJ., SkjorringeT., GjettingT.et al.2009. PhiC31 integrase induces a DNA damage response and chromosomal rearrangements in human adult fibroblasts. BMC Biotechnol, 9:31.
27.
LiuQ., PerezC.F., WangY.2006. Efficient site-specific integration of large transgenes by an enhanced herpes simplex virus/adeno-associated virus hybrid amplicon vector. J Virol, 80:1672–1679.
28.
MahL.J., El-OstaA., KaragiannisT.C.2010. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia, 24:679–686.
29.
MassieB., CoutureF., LamoureuxL.et al.1998. Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. J Virol, 72:2289–2296.
30.
MatesL., ChuahM.K., BelayE.et al.2009. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet, 41:753–761.
31.
MauckschC., AnejaM.K., HennenE.et al.2008. Cell type differences in activity of the Streptomyces bacteriophage phiC31 integrase. Nucleic Acids Res, 36:5462–5471.
32.
Meneses-AcostaA., DormondE., JacobD.et al.2008. Development of a suspension serum-free helper-dependent adenovirus production system and assessment of co-infection conditions. J Virol Methods, 148:106–114.
33.
MitchellR.S., BeitzelB.F., SchroderA.R.et al.2004. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol, 2:E234.
34.
MurnaneJ.P., YezziM.J., YoungB.R.1990. Recombination events during integration of transfected DNA into normal human cells. Nucleic Acids Res, 18:2733–2738.
35.
OhbayashiF., BalamotisM.A., KishimotoA.et al.2005. Correction of chromosomal mutation and random integration in embryonic stem cells with helper-dependent adenoviral vectors. Proc Natl Acad Sci U S A, 102:13628–13633.
36.
OlivaresE.C., HollisR.P., ChalbergT.W.et al.2002. Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol, 20:1124–1128.
QuennevilleS.P., ChapdelaineP., RousseauJ.et al.2004. Nucleofection of muscle-derived stem cells and myoblasts with phiC31 integrase: stable expression of a full-length-dystrophin fusion gene by human myoblasts. Mol Ther, 10:679–687.
39.
QuennevilleS.P., ChapdelaineP., RousseauJ.et al.2007. Dystrophin expression in host muscle following transplantation of muscle precursor cells modified with the phiC31 integrase. Gene Ther, 14:514–522.
40.
RaymondC.S., SorianoP.2007. High-efficiency FLP and PhiC31 site-specific recombination in mammalian cells. PLoS One, 2:e162.
41.
RecchiaA., PeraniL., SartoriD.et al.2004. Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol Ther, 10:660–670.
42.
RobertM.A., LinY., BendjelloulM.et al.2012. Strength and muscle specificity of a compact promoter derived from the slow troponin I gene in the context of episomal (gutless adenovirus) and integrating (lentiviral) vectors. J Gene Med, 14:746–760.
43.
SchaackJ., HoW.Y., FreimuthP.et al.1990. Adenovirus terminal protein mediates both nuclear matrix association and efficient transcription of adenovirus DNA. Genes Dev, 4:1197–1208.
SinnP.L., SauterS.L., MccrayP.B.Jr.2005. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors—design, biosafety, and production. Gene Ther, 12:1089–1098.
46.
SivalingamJ., KrishnanS., NgW.H.et al.2010. Biosafety assessment of site-directed transgene integration in human umbilical cord-lining cells. Mol Ther, 18:1346–1356.
47.
SmithM.C., BrownW.R., McewanA.R.et al.2010. Site-specific recombination by phiC31 integrase and other large serine recombinases. Biochem Soc Trans, 38:388–394.
48.
SoiferH.S., KasaharaN.2004. Retrotransposon-adenovirus hybrid vectors: efficient delivery and stable integration of transgenes via a two-stage mechanism. Curr Gene Ther, 4:373–384.
49.
StephenS.L., SivanandamV.G., KochanekS.2008. Homologous and heterologous recombination between adenovirus vector DNA and chromosomal DNA. J Gene Med, 10:1176–1189.
50.
ThyagarajanB., OlivaresE.C., HollisR.P.et al.2001. Site-specific genomic integration in mammalian cells mediated by phage phiC31 integrase. Mol Cell Biol, 21:3926–3934.
51.
ThyagarajanB., LiuY., ShinS.et al.2008. Creation of engineered human embryonic stem cell lines using phiC31 integrase. Stem Cells, 26:119–126.
52.
UmanaP., GerdesC.A., StoneD.et al.2001. Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol, 19:582–585.
53.
VetriniF., NgP.2010. Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives. Viruses, 2:1886–1917.
WoodardL.E., HillmanR.T., KeravalaA.et al.2010a. Effect of nuclear localization and hydrodynamic delivery-induced cell division on phiC31 integrase activity. Gene Ther, 17:217–226.
56.
WoodardL.E., KeravalaA., JungW.E.et al.2010b. Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma. PLoS One, 5:e11367.
57.
WurteleH., LittleK.C., ChartrandP.2003. Illegitimate DNA integration in mammalian cells. Gene Ther, 10:1791–1799.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
